K George Chandy1, Heike Wulff, Christine Beeton
1Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA. gchandy@uci.edu
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Selective potassium channel blockers targeting Kv1.3 and IKCa1 channels show therapeutic promise for immune disorders. Their distinct expression patterns in T cells change with activation and differentiation, offering specific immunomodulatory strategies.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: